Jacobio Pharmaceuticals Says Cash Runway Extends at Least Four Years

MT Newswires Live
05/19

Jacobio Pharmaceuticals (HKG:1167) said its cash runway extends at least four years, supported by about 2.10 billion yuan in cash and bank balances, capital-protected structured deposits, and available bank credit facilities, according to a Tuesday Hong Kong bourse filing.

The drug company said it has repurchased 747,800 shares for about HK$34.2 million as of May 18.

Jacobio also received a $100 million upfront payment from AstraZeneca under a strategic collaboration agreement, along with 8.6 million yuan in sales royalty payments from Allist for the June-to-December 2025 period, the filing said.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10